Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Open-Label Study To Evaluate The Efficacy And Safety Of A Contezolid, Delamanid and Bedaquiline-Containing Short Regimen For The Treatment Of Rifampicin-Resistant Pulmonary Tuberculosis

NCT06081361 is registered in ClinicalTrials.gov with Beijing Chest Hospital as lead sponsor.

NCT NCT06081361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06081361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Open-Label Study To Evaluate The Efficacy And Safety Of A Contezolid, Delamanid and Bedaquiline-Containing Short Regimen For The Treatment Of Rifampicin-Resistant Pulmonary Tuberculosis
Lead sponsor
Beijing Chest Hospital
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 22, 2023
Completion date
December 31, 2026
Enrollment
186 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary tuberculosis, rifampicin-resistant tuberculosis